Lexeo Therapeutics, Inc.

Equities

LXEO

US52886X1072

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
15.46 ^USD	-0.13%		+10.27%	+15.20%

May. 09	Lexeo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 01	Certain Options of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	CI

Lexeo Therapeutics, Inc. Announces Not to Stand for Reelection of Bernard Davitian as Director

April 22, 2024 at 08:11 am EDT

Lexeo Therapeutics, Inc. announced that on April 16, 2024, Bernard Davitian, director notified the company that he does not intend to stand for reelection as at the Company?s 2024 annual meeting of stockholders on June 25, 2024. Mr. Davitian?s notice not to stand for reelection is not the result of any disagreement with the Company on any matter relating to the Company?s operations, policies, or practices.

Latest news about Lexeo Therapeutics, Inc.

Lexeo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Certain Options of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	Apr. 30	CI
Certain Common Stock of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	Apr. 30	CI
Lexeo Therapeutics Signs License Deal With Cornell for Potential Friedreich Ataxia Cardiomyopathy Drug	Apr. 22	MT
Lexeo Therapeutics, Inc. Announces Not to Stand for Reelection of Bernard Davitian as Director	Apr. 22	CI
Lexeo Says AAV-Based Gene Therapy Candidate Gets US FDA's Fast Track Designation for Friedreich's Ataxia Cardiomyopathy	Apr. 16	MT
Lexeo Gets FDA Fast-Track Designation for LX2006 in Friedreich's Ataxia Cardiomyopathy	Apr. 16	DJ
Lexeo Therapeutics, Inc. Announces the U.S. Food and Drug Administration Grants Fast Track Designation for LX2006, an Aav-Based Gene Therapy Candidate for the Treatment of Friedreich?s Ataxia Cardiomyopathy	Apr. 16	CI
Lexeo Therapeutics, Inc.(NasdaqGM:LXEO) added to S&P Global BMI Index	Mar. 17	CI
Lexeo Therapeutics Raises $95 Million Via Private Placement of Shares	Mar. 13	MT
Lexeo Therapeutics, Inc. announced that it has received $94.999833 million in funding from a group of investors	Mar. 12	CI
RBC Raises Price Target on Lexeo Therapeutics to $24 From $22, Cites 'Solid' Friedreich's Ataxia Data; Outperform, Speculative Risk Kept	Mar. 12	MT
Lexeo Therapeutics' Q4 Net Loss Narrows; Cash Runway Extended to 2027 -- Shares Jump Pre-Bell	Mar. 11	MT
LEXEO: ENTERED INTO COMMON STOCK PURCHASE AGREEMENT TO…	Mar. 11	RE
Lexeo Therapeutics, Inc. announced that it expects to receive $94.999833 million in funding	Mar. 10	CI
Lexeo Therapeutics Promotes Sandi See Tai to Chief Development Officer, Makes Other Appointments	Feb. 05	MT
Lexeo Therapeutics, Inc. Strengthens Clinical Development Leadership with New Executive Appointments	Feb. 05	CI
Lexeo Soars After Gene Therapy for Cardiac Disorder Receives Orphan Drug, Fast Track Designations	Dec. 18	MT
Lexeo Therapeutics, Inc.(NasdaqGM:LXEO) added to S&P TMI Index	Dec. 18	CI
Top Premarket Decliners	Dec. 13	MT
Chardan Initiates Lexeo Therapeutics With Buy Rating, $23 Price Target	Nov. 28	MT
Stifel Starts Lexeo Therapeutics With Buy Rating, $20 Price Target	Nov. 28	MT
RBC Initiates Lexeo Therapeutics at Outperform, Speculative Risk With $22 Price Target Amid 'Undemanding' Valuation, Upcoming Catalysts	Nov. 28	MT
JPMorgan Starts Lexeo Therapeutics With Overweight Rating, $20 Price Target	Nov. 28	MT
Lexeo Therapeutics Insider Bought Shares Worth $2,499,992, According to a Recent SEC Filing	Nov. 10	MT

Chart Lexeo Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).

Sector

Biotechnology & Medical Research

Calendar

2024-06-25 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.48 USD

Average target price

21.4 USD

Spread / Average Target

+38.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LEXEO THERAPEUTICS, INC.	+15.20%	510M
MODERNA, INC.	+67.53%	62.86B
IQVIA HOLDINGS INC.	-0.77%	41.38B
LONZA GROUP AG	+45.66%	40.38B
CELLTRION, INC.	-10.72%	27.64B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.46B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.9B
BIO-TECHNE CORPORATION	+4.70%	12.67B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.27B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research